|
Accupril |
|
Accupril |
30 - 5 mg Tablets |
|
Male
 |
|
Accupril |
60 - 5 mg Tablets |
|
|
Accupril |
90 - 5 mg Tablets |
|
|
Accupril |
30 - 10 mg Tablets |
|
USA
Pharmacies and Physicians!
FDA Approved Drug! |
|
Accupril |
60 - 10 mg Tablets |
|
|
Accupril |
90 - 10 mg Tablets |
|
|
Accupril |
30 - 20 mg Tablets |
|
|
Accupril |
60 - 20 mg Tablets |
|
|
Accupril |
90 - 20 mg Tablets |
|
|
Accupril |
30 - 40 mg Tablets |
|
Female
 |
|
Accupril |
60 - 40 mg Tablets |
|
|
Accupril |
90 - 40 mg Tablets |
|
Accupril Hypertension Medication
Drug Information
The following information is
intended to supplement, not substitute for, the expertise and
judgment of your physician, pharmacist or other healthcare
professional. It should not be construed to indicate that use of
the drug is safe, appropriate, or effective for you. Consult
your healthcare professional before using this drug.
Online Accupril Use Indication:
Monotherapy: The recommended initial dosage of ACCUPRIL in
patients not on diuretics is 10 mg once daily. Depending upon
clinical response, patient's dosage may be titrated (by doubling
the dose) to a maintenance dosage of 20 to 40 mg/day given as a
single dose or divided into two doses. Generally, dosage
adjustments should be made at intervals of four weeks or
according to patient's response. Long-term control is maintained
in most patients with a single daily dosage regimen.
Antihypertensive activity commences within one hour with peak
effects usually achieved by two to four hours after dosing.
Achievement of maximum blood pressure lowering effects may
require two weeks of therapy in some patients.
Concomitant Diuretics: In patients who are also being treated
with a diuretic, the initial dosage of ACCUPRIL is 5 mg in order
to determine if excess hypotension will occur. The dosage should
subsequently be titrated (as described above) to the optimal
response (see SIDE EFFECTS AND SPECIAL PRECAUTIONS).
Congestive Heart Failure:
The recommended initial dosage in patients with congestive heart
failure due to unresponsive systolic left ventricular failure of
various aetiologies in which afterload reduction is advocated,
is a single 5 mg dose, following which the patient should be
monitored closely for symptomatic hypotension. Patients may be
titrated up to 40 mg per day given in two doses with concomitant
diuretic and/or cardiac glycoside therapy. Patients can,
however, normally be maintained effectively on doses of 10 to 20
mg per day given in one or two doses with concomitant therapy.
Hypertension Medication Accupril Side Effects:
The most
frequent clinical adverse reactions in controlled trials with
Accupril were (in descending order of frequency) headache,
dizziness, rhinitis, coughing, upper respiratory tract
infection, fatigue, dyspepsia, nausea and vomiting, myalgia,
abdominal pain, diarrhoea, insomnia, paresthesia, nervousness,
asthenia, hypotension and leucopenia.
Less frequent adverse events that have been reported include:
palpitations, vasodilatation, dry mouth or throat, pancreatitis,
vertigo, nervousness, depression, somnolence, pruritus, rash,
exfoliative dermatitis, pemphigus, increased perspiration,
alopecia, urinary tract infection, impotence, edema, arthralgia,
hemolytic anaemia, and angioedema.
Creatinine and Blood Urea Nitrogen: Increases (>1,25 times the
upper limit of normal) in serum creatinine and blood urea
nitrogen may occur especially with concomitant diuretic therapy.
Precautions on using Accupril Hypertension Medication
Angioedema:
Angioedema, including laryngeal edema, may occur, especially
following the first dose of ACCUPRIL. Patients should be so
advised and told to report immediately any signs or symptoms
suggesting angioedema (swelling of face, eyes, lips, tongue,
difficulty in breathing) and to discontinue medication until
they have consulted with their physician.
If laryngeal stridor or angioedema of the face, tongue, or
glottis occur, treatment with ACCUPRIL should be discontinued
immediately, the patient treated appropriately in accordance
with accepted medical care, and carefully observed until the
swelling disappears. Angioedema associated with laryngeal
involvement may be fatal. Where there is involvement of the
tongue, glottis, or larynx likely to cause airway obstruction,
appropriate therapy e.g., subcutaneous adrenalin solution 1:1000
(0,3 to 0,5 mL) should be promptly administered.
|